Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Healthy Participants 5Neoplasms 3Solid Tumor, Adult 2Carcinoma, Non-Small-Cell Lung 2cMET-dysregulated Advanced Solid Tumors 1TP53 Y220C Mutation 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pain 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Liver Cirrhosis 1Leiomyosarcoma 1Healthy Volunteers 1Healthy Adult Participants 1Healthy 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Chronic Cough 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Non-small Cell Lung Cancer 1

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × TP53 Y220C Mutation × Rosuvastatin Calcium × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡